TITLE

Rivaroxaban: Another Warfarin Replacement

PUB. DATE
January 2011
SOURCE
Travel Medicine Advisor;Jan2011 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to pharmacology in the U.S. A study shows that rivaroxaban, an oral drug factor Xa inhibitor, is as effective as warfarin in preventing stroke and blood clots in patients with nonvalvular atrial fibrillation. A study published in "Annals of Internal Medicine" examines drug adherence by assessing the rate of prescriptions abandoned at the pharmacy. It also notes on the drug approval actions of the Food and Drug Administration (FDA) for Gardasil and duloxetine.
ACCESSION #
56671765

 

Related Articles

  • New Antiplatelet Drug Approved.  // Clarendon Enterprise (TX);8/20/2009, Vol. 20 Issue 34, p5 

    The article reports on the approval of prasugrel, an antiplatelet drug by the U.S. Food and Drug Administration (FDA).

  • New indication for Pradaxa.  // Australian Journal of Pharmacy;Jun2011, Vol. 92 Issue 1093, p44 

    The article announces the approval of the drug Pradaxa for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Australia.

  • The National Alliance for Thrombosis and Thrombophilia issues statement on recommendation for rivaroxaban's approval. Hogan, Tom; Henry, David B. // Hem/Onc Today;4/10/2009, Vol. 10 Issue 7, p4 

    The article reports that the National Alliance for Thrombosis and Thrombophilia (NATT) has issued a statement on recommendation for the approval of oral anticoagulant rivaroxaban in the U.S.

  • Apixaban superior to warfarin in trial. Elliott, William T. // Neurology Alert;Feb2013 Pharmacology Watch, p1 

    The article reports on the approval made by the U.S. Food and Drug Administration for apixaban third novel oral anticoagulant marketed by Eliquis by Bristol-Myers Squibb and Pfizer, for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).

  • Cymbalta for GAD.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA11 

    The article reports on the approval of the drug Cymbalta from Lilly for the maintenance treatment of generalized anxiety disorder (GAD) by the U.S. Food and Drug Administration.

  • Rivaroxaban for atrial fibrillation patients.  // OB/GYN Clinical Alert;Jan2012 Pharmacology, p1 

    The article reports on the approval of the pharmaceutical drug and oral anticoagulant Rivaroxaban (Xarelto) by Janssen Pharmaceuticals Inc., for its use in patients with atrial fibrillation for reducing the risk of strokes and rate of intracranial hemorrhage in them.

  • A New Hemophilia Drug Takes Some Risk Out Of Treatment. Vernarec, Emil; Mangan, Doreen // RN;Sep2003, Vol. 66 Issue 9, p95 

    Reports on the approval of a recombinant DNA-derived clotting factor by the U.S. Food and Drug Administration. Market name; Indications; Risk of allergic-like reactions.

  • Apixaban. Cada, Dennis J.; Levien, Terri L.; Baker, Danial E. // Hospital Pharmacy;Jun2013, Vol. 48 Issue 6, p494 

    The article discusses a review of the formulary drug Apixaban which is used to reduce stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation. Apixaban is a direct-acting, selective, reversible oral inhibitor of factor Xa that converts prothrombin to thrombin. It is...

  • Site-Level Variation in and Practices Associated With Dabigatran Adherence. Shore, Supriya; Ho, P. Michael; Lambert-Kerzner, Anne; Glorioso, Thomas J.; Carey, Evan P.; Cunningham, Fran; Longo, Lisa; Jackevicius, Cynthia; Rose, Adam; Turakhia, Mintu P. // JAMA: Journal of the American Medical Association;4/14/2015, Vol. 313 Issue 14, p1443 

    IMPORTANCE Unlike warfarin, which requires routine laboratory testing and dose adjustment, target-specific oral anticoagulants like dabigatran do not. However, optimal follow-up infrastructure and modifiable site-level factors associated with improved adherence to dabigatran are unknown....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics